Comparison of myxovirus resistance gene 2 expression among adult and juvenile SLE Iraqi patients
DOI:
https://doi.org/10.59796/jcst.V15N2.2025.97Keywords:
juvenile-onset SLE, adult-onset SLE, MX2 geneAbstract
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple systems in the body. The disease may also impact juveniles (jSLE), but are less frequent. SLE is characterized by the excessive production of auto-antibodies, and genetic background that is not fully comprehended. The human Mxyovirus resistance gene (MX2), classified as an immune regulatory gene, has not yet been researched in juvenile-onset-SLE. There are only a few studies on its connection to rheumatic disease in adults. The current study aimed to investigate its expression and its correlation with disease activity in different ages. This study included 50 patients with SLE, 25 adults and 25 juveniles who all met the ACR criteria, and a control group of 30 healthy individuals, Total RNA was obtained by PBMCs from fresh whole blood samples of all participants to detect human (MX2) levels through quantitative real-time polymerase chain reaction (qRT-PCR), and disease activity was assessed using the systemic erythematosus disease activity index score 2000. The human (MX2) gene was overexpressed in all percipients involved, and there were no statistical differences between the studied group in expression rate p=0.76, There was a non-significant p=0.092 weak negative correlation r=-0.351 between the fold of gene expression and the SLEDAI-2k score. The SLEDAI-2k of (jSLE) and (aSLE) indicated a statistically significant difference between the two groups (p=0.04). Understanding the genes linked to SLE is extremely important, as MX2 could potentially serve as a diagnostic marker, and may also lead to further research opportunities.
References
Abd El Monem Teama, M., Adham El-Mohamdy, M., Abdellah Abdullah Mahmoud, F., & Mohammed Badr, F. (2021). Autoantibody Profile of Egyptian Juvenile Systemic Lupus Erythematosus Patients and Its Association with Clinical Characteristics and Disease Activity. Open Access Rheumatology: Research and Reviews, 13, 201-212. https://doi.org/10.2147/OARRR.S317315
Al-Rayahi, I. A. M., Browning, M. J., & Stover, C. (2017). Tumour cell conditioned medium reveals greater M2 skewing of macrophages in the absence of properdin. Immunity, Inflammation and Disease, 5(1), 68–77. https://doi.org/10.1002/iid3.142
Avar-Aydın, P. Ö., & Brunner, H. I. (2024). Revisiting Childhood-Onset Systemic Lupus Erythematosus. Turkish Archives of Pediatrics, 59(4), 336-344. https://doi.org/10.5152/TurkArchPediatr.2024.24097
Betancor, G., Jimenez-Guardeño, J. M., Lynham, S., Antrobus, R., Khan, H., Sobala, A., ... & Malim, M. H. (2021). MX2-mediated innate immunity against HIV-1 is regulated by serine phosphorylation. Nature microbiology, 6(8), 1031-1042. https://doi.org/10.1038/s41564-021-00937-5
Cary, N. (2012). Statistical analysis system, User's guide. Statistical. Version 9. SAS. Inst. Inc. USA.
Catalina, M. D., Owen, K. A., Labonte, A. C., Grammer, A. C., & Lipsky, P. E. (2020). The pathogenesis of systemic lupus erythematosus: harnessing big data to understand the molecular basis of lupus. Journal of Autoimmunity, 110, Article 102359. https://doi.org/10.1016/j.jaut.2019.102359
Ceccarelli, F., Natalucci, F., Olivieri, G., Perricone, C., Pirone, C., Spinelli, F. R., ... & Conti, F. (2021). Erosive arthritis in systemic lupus erythematosus: not only Rhupus. Lupus, 30(13), 2029-2041. https://doi.org/10.1177/09612033211051637
Charras, A. M. A. N. D. I. N. E., Smith, E., & Hedrich, C. M. (2021). Systemic lupus erythematosus in children and young people. Current Rheumatology Reports, 23(20), 1-15. https://doi.org/10.1007/s11926-021-00985-0
Cooles, F. A., & Isaacs, J. D. (2022). The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease. The Lancet Rheumatology, 4(1), e61-e72. https://doi.org/10.1016/S2665-9913(21)00254-X
Coss, S. L., Zhou, D., Chua, G. T., Aziz, R. A., Hoffman, R. P., Wu, Y. L., ... & Yu, C. Y. (2023). The complement system and human autoimmune diseases. Journal of autoimmunity, 137, Article 102979. https://doi.org/10.1016/j.jaut.2022.102979
Damoiseaux, J., & van Beers, J. (2023). Autoantibodies to dsDNA in the diagnosis, classification and follow-up of patients with systemic lupus erythematosus. Journal of Translational Autoimmunity, 6, Article 100191. https://doi.org/10.1016/j.jtauto.2023.100191
Demers-Mathieu, V. (2023). Optimal selection of IFN-α-inducible genes to determine type I interferon signature improves the diagnosis of systemic lupus erythematosus. Biomedicines, 11(3), Article 864. https://doi.org/10.3390/biomedicines11030864
Deng, Y., & Tsao, B. P. (2017). Updates in lupus genetics. Current Rheumatology Reports, 19, 1-13. https://doi.org/10.1007/s11926-017-0695-z
Dey, M., Parodis, I., & Nikiphorou, E. (2021). Fatigue in systemic lupus erythematosus and rheumatoid arthritis: a comparison of mechanisms, measures and management. Journal of Clinical Medicine, 10(16), Article 3566. https://doi.org/10.3390/jcm10163566
Dicks, M. D., Goujon, C., Pollpeter, D., Betancor, G., Apolonia, L., Bergeron, J. R., & Malim, M. H. (2016). Oligomerization requirements for MX2-mediated suppression of HIV-1 infection. Journal of Virology, 90(1), 22-32. https://doi.org/10.1128/jvi.02247-15
El-Garf, K., El-Garf, A., Gheith, R., Badran, S., Salah, S., Marzouk, H., Farag, Y., Khalifa, I., & Mostafa, N. (2021). A comparative study between the disease characteristics in adult-onset and childhood-onset systemic lupus erythematosus in Egyptian patients attending a large university hospital. Lupus, 30(2), 211–218. https://doi.org/10.1177/0961203320972778
Gilliam, B. E., Ombrello, A. K., Burlingame, R. W., Pepmueller, P. H., & Moore, T. L. (2012). Measurement of Autoantibodies in Pediatric-Onset Systemic Lupus Erythematosus and Their Relationship with Disease-Associated Manifestations. Seminars in Arthritis and Rheumatism, 41(6), 840-848. https://doi.org/10.1016/j.semarthrit.2011.09.009
Gladman, D. D., Ibaņez, D., & Urowitz, M. B. (2002). Systemic lupus erythematosus disease activity index 2000. The Journal of Rheumatology, 29(2), 288-291.
Gounden, V., Bhatt, H., & Jialal, I. (2024). Renal function tests. StatPearls. StatPearls Publishing. Retrived from https://www.ncbi.nlm.nih.gov/sites/books/NBK507821/
Haller, O., Staeheli, P., Schwemmle, M., & Kochs, G. (2015). Mx GTPases: dynamin-like antiviral machines of innate immunity. Trends in Microbiology, 23(3), 154-163. https://doi.org/10.1016/j.tim.2014.12.003
Hochberg, M. C. (1997). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism, 40(9), 1725-1725. https://doi.org/10.1002/art.1780400928
Hsu, T. C., Yang, Y. H., Wang, L. C., Lee, J. H., Yu, H. H., Lin, Y. T., ... & Chiang, B. L. (2023). Risk factors for subsequent lupus nephritis in patients with juvenile-onset systemic lupus erythematosus: a retrospective cohort study. Pediatric Rheumatology, 21(1), Article 28. https://doi.org/10.1186/s12969-023-00806-x
Jawad kadhum, M. A., Al-timari, U. S. & Al-Rayahi, I. A. (2021). Assessments of Biochemical, Immunological and Hematological Parameters in Iraqi Pediatrics SLE patient’s Compared to Healthy Controls. Al-Nisour Journal for Medical Sciences, 3(1), 63-77. https://doi.org/10.70492/2664-0554.1059
Jiang, Q., Li, R. X., & Hu, P. (2022). Raynaud’s phenomenon in childhood-onset systemic lupus erythematous. Archives of Medical Science: AMS, 18(6), Article 1716. https://doi.org/10.5114/aoms/153469
Juraleviciute, M., Nsengimana, J., Newton-Bishop, J., Hendriks, G. J., & Slipicevic, A. (2021). MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy. Cancer Medicine, 10(8), 2840-2854. https://doi.org/10.1002/cam4.3846
Juraleviciute, M., Pozniak, J., Nsengimana, J., Harland, M., Randerson‐Moor, J., Wernhoff, P., ... & Slipicevic, A. (2020). MX 2 is a novel regulator of cell cycle in melanoma cells. Pigment Cell & Melanoma Research, 33(3), 446-457. https://doi.org/10.1111/pcmr.12837
Justiz Vaillant, A. A., Goyal, A., & Varacallo, M. (2023). Systemic Lupus Erythematosus StatPearls: StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.
Kim, H., Levy, D. M., Silverman, E. D., Hitchon, C., Bernatsky, S., Pineau, C., ... & Pope, J. E. (2019). A comparison between childhood and adult onset systemic lupus erythematosus adjusted for ethnicity from the 1000 Canadian Faces of Lupus Cohort. Rheumatology, 58(8), 1393-1399. https://doi.org/10.1093/rheumatology/kez006
Landolt-Marticorena, C., Bonventi, G., Lubovich, A., Ferguson, C., Unnithan, T., Su, J., ... & Wither, J. (2009). Lack of association between the interferon-α signature and longitudinal changes in disease activity in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 68(9), 1440-1446. https://doi.org/10.1136/ard.2008.093146
Lang, R., Li, H., Luo, X., Liu, C., Zhang, Y., Guo, S., ... & Yu, Y. (2022). Expression and mechanisms of interferon-stimulated genes in viral infection of the central nervous system (CNS) and neurological diseases. Frontiers in Immunology, 13, Article 1008072. https://doi.org/10.3389/fimmu.2022.1008072
Lao, C., White, D., Rabindranath, K., Van Dantzig, P., Foxall, D., Aporosa, A., & Lawrenson, R. (2023). Incidence and prevalence of systemic lupus erythematosus in New Zealand from the national administrative datasets. Lupus, 32(8), 1019-1027. https://doi.org/10.1177/09612033231182203
Liu, J., Berthier, C. C., & Kahlenberg, J. M. (2017). Enhanced Inflammasome Activity in Systemic Lupus Erythematosus Is Mediated via Type I Interferon–Induced Up-Regulation of Interferon Regulatory Factor 1. Arthritis & rheumatology, 69(9), 1840-1849. https://doi.org/10.1002/art.40166
Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25(4), 402-408. https://doi.org/10.1006/meth.2001.1262
Massias, J. S., Smith, E. M. D., Al-Abadi, E., Armon, K., Bailey, K., Ciurtin, C., ... & Hedrich, C. M. (2020). Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus, 29(5), 474-481. https://doi.org/10.1177/0961203320909156
Meng, X. W., Cheng, Z. L., Lu, Z. Y., Tan, Y. N., Jia, X. Y., & Zhang, M. (2022). MX2: identification and systematic mechanistic analysis of a novel immune-related biomarker for systemic lupus erythematosus. Frontiers in Immunology, 13, Article 978851. https://doi.org/10.3389/fimmu.2022.978851
Moschonas, G. D., Delhaye, L., Cooreman, R., Hüsers, F., Bhat, A., Sutter, D. D., ... & Saelens, X. (2023). MX2 restricts HIV-1 and herpes simplex virus type 1 by forming cytoplasmic biomolecular condensates that mimic nuclear pore complexes. BioRxiv, 2023-06. https://doi.org/10.1101/2023.06.22.545931
Mummert, E., Fritzler, M. J., Sjöwall, C., Bentow, C., & Mahler, M. (2018). The clinical utility of anti-double-stranded DNA antibodies and the challenges of their determination. Journal of Immunological Methods, 459, 11-19. https://doi.org/10.1016/j.jim.2018.05.014
Nandakumar, K. S., & Nündel, K. (2022). Systemic lupus erythematosus-predisposition factors, pathogenesis, diagnosis, treatment and disease models. Frontiers In Immunology, 13, Article 1118180. https://doi.org/10.3389/fimmu.2022.1118180
Nikpour, M., Dempsey, A. A., Urowitz, M. B., Gladman, D. D., & Barnes, D. A. (2008). Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Annals of the Rheumatic Diseases, 67(8), 1069-1075. https://doi.org/10.1136/ard.2007.074765
Oon, S., Wilson, N. J., & Wicks, I. (2016). Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clinical & Translational Immunology, 5(5), Article e79. https://doi.org/10.1038/cti.2016.26
Orme, M. E., Voreck, A., Aksouh, R., & Schreurs, M. W. J. (2022). Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review. The Journal of Applied Laboratory Medicine, 7(1), 221-239. https://doi.org/10.1093/jalm/jfab146
Palanichamy, A., Bauer, J. W., Yalavarthi, S., Meednu, N., Barnard, J., Owen, T., ... & Anolik, J. H. (2014). Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. The Journal of Immunology, 192(3), 906-918. https://doi.org/10.4049/jimmunol.1302112
Petri, M., Fu, W., Ranger, A., Allaire, N., Cullen, P., Magder, L. S., & Zhang, Y. (2019). Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus. BMC Medical Genomics, 12(4), 1-9. https://doi.org/10.1186/s12920-018-0468-1
Pinheiro, S. V. B., Dias, R. F., Fabiano, R. C. G., & Araujo, S. D. A. (2018). Pediatric lupus nephritis. Brazilian Journal of Nephrology, 41, 252-265. https://doi.org/10.1590/2175-8239-jbn-2018-0097
Pisetsky, D. S., Bossuyt, X., & Meroni, P. L. (2019). ANA as an entry criterion for the classification of SLE. Autoimmunity Reviews, 18(12), Article 102400. https://doi.org/10.1016/j.autrev.2019.102400
Postal, M., Vivaldo, J. F., Fernandez-Ruiz, R., Paredes, J. L., Appenzeller, S., & Niewold, T. B. (2020). Type I interferon in the pathogenesis of systemic lupus erythematosus. Current Opinion in Immunology, 67, 87-94. https://doi.org/10.1016/j.coi.2020.10.014
Qian, D., Liu, L., Zhu, T., Wen, L., Zhu, Z., Yin, X., ... & Zhang, X. (2020). JAK2 and PTPRC mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clinical Rheumatology, 39, 443-448. https://doi.org/10.1007/s10067-019-04778-w
Rahman, S., Sagar, D., Hanna, R. N., Lightfoot, Y. L., Mistry, P., Smith, C. K., ... & Casey, K. A. (2019). Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 78(7), 957-966. https://doi.org/10.1136/annrheumdis-2018-214620
Robinson, G. A., Peng, J., Dönnes, P., Coelewij, L., Naja, M., Radziszewska, A., ... & Jury, E. C. (2020). Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach. The Lancet Rheumatology, 2(8), e485-e496. https://doi.org/10.1016/S2665-9913(20)30168-5
Rodsaward, P., Chottawornsak, N., Suwanchote, S., Rachayon, M., Deekajorndech, T., Wright, H. L., ... & Chiewchengchol, D. (2021). The clinical significance of antinuclear antibodies and specific autoantibodies in juvenile and adult systemic lupus erythematosus patients. Asian Pacific Journal of Allergy and Immunology, 39(4), 279-286. https://doi.org/10.12932/AP-211218-0465
Saferding, V., & Blüml, S. (2020). Innate immunity as the trigger of systemic autoimmune diseases. Journal of Autoimmunity, 110, Article 102382. https://doi.org/10.1016/j.jaut.2019.102382
Samanta, M., Nandi, M., Mondal, R., Hazra, A., Sarkar, S., Sabui, T., ... & Biswas, A. (2017). Childhood lupus nephritis: 12 years of experience from a developing country’s perspective. European Journal of Rheumatology, 4(3), 178-183. https://doi.org/10.5152/eurjrheum.2017.16117
Sanayama, Y., Ikeda, K., Saito, Y., Kagami, S. I., Yamagata, M., Furuta, S., ... & Nakajima, H. (2014). Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome‐wide DNA microarray. Arthritis & Rheumatology, 66(6), 1421-1431. https://doi.org/10.1002/art.38400
Sandhu, V., & Quan, M. (2017). SLE and serum complement: causative, concomitant or coincidental?. The Open Rheumatology Journal, 11, Article 113. https://doi.org/10.2174/1874312901711010113
Shen, M., Duan, C., Xie, C., Wang, H., Li, Z., Li, B., & Wang, T. (2022). Identification of key interferon-stimulated genes for indicating the condition of patients with systemic lupus erythematosus. Frontiers in Immunology, 13, Article 962393. https://doi.org/10.3389/fimmu.2022.962393
Sippl, N., Faustini, F., Rönnelid, J., Turcinov, S., Chemin, K., Gunnarsson, I., & Malmström, V. (2021). Arthritis in systemic lupus erythematosus is characterized by local IL-17A and IL-6 expression in synovial fluid. Clinical & Experimental Immunology, 205(1), 44-52. https://doi.org/10.1111/cei.13585
Soares, L., Matos, A. R., Vieira, M. M., Cruz, R., Caixas, U., Matos Sr, A. R., & Caixas Sr, U. (2022). Generalized lymphadenopathy as the first manifestation of systemic lupus erythematosus. Cureus, 14(10), Article e30089. https://doi.org/10.7759/cureus.30089
Tay, S. H., Celhar, T., & Fairhurst, A. M. (2020). Low‐density neutrophils in systemic lupus erythematosus. Arthritis & Rheumatology, 72(10), 1587-1595. https://doi.org/10.1002/art.41395
Tektonidou, M. G., Lewandowski, L. B., Hu, J., Dasgupta, A., & Ward, M. M. (2017). Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Annals of the Rheumatic Diseases, 76(12), 2009-2016. https://doi.org/10.1136/annrheumdis-2017-211663
Tian, J., Zhang, D., Yao, X., Huang, Y., & Lu, Q. (2023). Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Annals of the Rheumatic Diseases, 82(3), 351-356. https://doi.org/10.1136/ard-2022-223035
Trindade, V. C., Carneiro-Sampaio, M., Bonfa, E., & Silva, C. A. (2021). An update on the management of childhood-onset systemic lupus erythematosus. Pediatric Drugs, 23(4), 331-347. https://doi.org/10.1007/s40272-021-00457-z
Vyasam, S., Punnen, A., Jeyaseelan, V., Prakash, J. J., & Kumar, S. (2023). Autoantibodies in Pediatric Systemic Lupus Erythematosus: Cluster Analysis and its Clinical Implications in Indian Children. Indian Journal of Rheumatology, 18(1), 35-39. https://doi.org/10.4103/injr.injr_129_21
Wallace, M. (2021). The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12–15 years—United States, May 2021. Morbidity and Mortality Weekly Report (MMWR), 70(20), 749-752. https://doi.org/10.15585/mmwr.mm7020e1
Wang, Y. X., Niklasch, M., Liu, T., Wang, Y., Shi, B., Yuan, W., ... & Wen, Y. M. (2020). Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication. Journal of Hepatology, 72(5), 865-876. https://doi.org/10.1016/j.jhep.2019.12.009
Webber, D., Cao, J., Dominguez, D., Gladman, D. D., Levy, D. M., Ng, L., ... & Hiraki, L. T. (2020). Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. Rheumatology, 59(1), 90-98. https://doi.org/10.1093/rheumatology/kez220
Wiesauer, I., Gaumannmüller, C., Steinparzer, I., Strobl, B., & Kovarik, P. (2015). Promoter occupancy of STAT1 in interferon responses is regulated by processive transcription. Molecular and Cellular Biology, 35(4), 716-727. https://doi.org/10.1128/MCB.01097-14
Xing, C., Trivedi, J., Bitencourt, N., Burns, D. K., Reisch, J. S., & Cai, C. (2024). Myxovirus resistance protein A (MxA) expression in myositides: Sarcoplasmic expression is common in both dermatomyositis and lupus myositis. Muscle & Nerve, 69(5), 548-555. https://doi.org/10.1002/mus.28066
Yi, D. R., An, N., Liu, Z. L., Xu, F. W., Raniga, K., Li, Q. J., ... & Cen, S. (2019). Human MxB inhibits the replication of hepatitis C virus. Journal of Virology, 93(1), 10-1128. https://doi.org/10.1128/jvi.01285-18
Zhao, M., Zhou, Y., Zhu, B., Wan, M., Jiang, T., Tan, Q., ... & Lu, Q. (2016). IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 75(11), 1998-2006. https://doi.org/10.1136/annrheumdis-2015-208410
Zhao, X., Duan, L., Cui, D., & Xie, J. (2023). Exploration of biomarkers for systemic lupus erythematosus by machine-learning analysis. BMC Immunology, 24(1), 44. https://doi.org/10.1186/s12865-023-00581-0
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Journal of Current Science and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
